

## Anti-CD8 alpha/Lyt-2 [YTS 169.4] Vivopure 10 mg Ab00166-2.3-VPT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric mouse antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Mouse IgG2a, Fc Silent<sup>™</sup>, Kappa

Clone Number: YTS 169.4

Alternative Name(s) of Target: Leu2; CD8; CD8A; CD8a molecule; CD8a antigen; Leu2 T-lymphocyte

antigen; Lyt-2; Lyt2OKT8; p32T-cell antigen Leu2; T-cell antigen; T cell co-receptor; T-cell surface

glycoprotein CD8 alpha chain; T-cell surface glycoprotein Lyt-2; T8 T-cell antigen

**UniProt Accession Number of Target Protein:** P01731 **Published Application(s):** Depletion, in vivo, FC, IHC, IHC-Fr

**Published Species Reactivity: Mouse** 

Immunogen: Murine CD8 (Lyt-2).

**Specificity:** This antibody recognises the murine CD8 cell surface antigen expressed by a subset of T lymphocytes.

**Application Notes:** The antibody has been shown to show depleting activity *in vivo*. Mice have two alleles for CD8, Lyt2.1, and Lyt2.2, which are restricted to certain mouse strains. Lyt2.1, for example, is expressed in the mouse strains CBA, AKR, C3H, and DBA, whereas Lyt2.2 is expressed in the mouse strains BALB/c and C57BL/6 (B/6). YTS 169.4 was originally raised against CBA mouse thymocytes. However, there are publications in which it has been used in C57BL/6 and BALB/c mice, wherein it was used specifically as a pan-reactive Lyt2 reagent (Tavaré et al., 2014; PMID: 24390540).

**Antibody First Published in:** Cobbold et al. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo Nature. 1984 Dec;312(5994):548-51. doi: 10.1038/312548a0 PMID:6150440

**Note on publication:** The original publication describes the generation of YTS 169.4 and demonstrates the efficacy of unmodified monoclonal antibodies for in vivo depletion of cells and their potential for selectively manipulating different aspects of the immune response.

## **Product Form**

**Size:** 10 mg Vivopure products are produced at high purity (>98%), low endotoxin (<0.5 EU/mg) and are formulated without preservatives. As a result Vivopure products are the ideal choice for in vivo research applications.

Purification: Protein A affinity purified

**Supplied In:** PBS only, with >98% antibody purity and <1 EU/mg guaranteed.

**Storage Recommendation:** All vivopure products are formulated in PBS only without addition of preservatives. To ensure optimal storage and prevent microbial contamination, only open and dispense under sterile conditions.

**Concentration:** >=1mg (see vial label for exact conc)

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.